テラノスティック抗体コンジュガート:癌における最近の動向と応用に関するレビュー
Keyvan Kheyrolahzadeh1, Maryam Mojahedi1, Mohammad Reza Tohidkia1
1Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran.
Bioorganic chemistry
|August 29, 2025
まとめ
抗体-薬剤結合体 (ADC) と抗体-放射性核酸結合体 (ARC) は 標的型がん治療法であり,理想的な"魔法弾"に近いものです. これらの免疫結合剤は,選択的にがん細胞を標的として治療と診断の有効性を高めます.
科学分野:
- 腫瘍学
- 免疫療法
- 放射化学
背景:
- 抗体-薬剤結合体 (ADC) と抗体-放射性核酸結合体 (ARC) は,高度な標的療法である.
- この免疫結合体は 百年の歴史を模倣しています
- 魔法の弾丸
- 病気を正確に標的にするコンセプト
研究 の 目的:
- 治療用ADCとセラノスティックARCの開発をレビューする.
- 標的外効果を最小限に抑えながら 選択的に腫瘍細胞を標的にする効果を分析する
- 免疫結合基のセラノスティクスの将来の研究と開発に関する洞察を提供すること.
主な方法:
- 抗体-薬物結合体 (ADCs) と抗体-放射性核酸結合体 (ARCs) に関する現在の文献のレビュー.
- ターゲティング戦略,コンジュガーション技術,ペイロード選択,ターゲティングメカニズムの分析.
- 臨床開発の状況と患者のアウトカムデータの評価
主要な成果:
- 15以上のADCとARCがセラノスティックに使用され,さらに多くのADCが開発中です.
- 免疫結合剤は,治療の選択肢を拡大し,がんの理解を向上させるのに有意義な可能性を示しています.
- ADC と ARC の開発における主要な戦略と最近の進歩が特定されました.
結論:
- ADCsとARCsは標的型がん治療と診断における大きな進歩を表しています.
- ターゲティング,コンジュガーション,ペイロードの最適化に関する継続的な研究が不可欠です.
- これらの薬剤は腫瘍学における患者の成果を改善する見込みです.
さらに関連する動画
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Hybridoma Technology
15.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.3K
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509


